Citation

  • Authors: Chen, Y. X., Zhang, M., Cai, Y., Zhao, Q., Dai, W.
  • Year: 2015
  • Journal: Biochem Biophys Res Commun 465 732-8
  • Applications: in vitro / siRNA / INTERFERin
  • Cell types:
    1. Name: Mouse primary VSMCs
      Description: Mouse primary visceral smooth muscle cells.
    2. Name: Mouse peritoneal macrophages
      Description: Mouse primary peritoneal macrophage

Method

20 nM siRNA.

Abstract

Activation of the silent mating type information regulation 2 homolog 1 (SIRT1) has been shown consistent antiinflammatory function. However, little information is available on the function of SIRT1 during Angiotensin II (AngII)-induced atherosclerosis. Here we report atheroprotective effects of sirt1 activation in a model of AngII-accelerated atherosclerosis, characterized by suppression pro-inflammatory transcription factors Nuclear transcription factor (NF)-kappaB and Signal Transducers and Activators of Transcription. (STAT) signaling pathway, and atherosclerotic lesion macrophage content. In this model, administration of the SIRT1 agonist SRT1720 substantially attenuated AngII-accelerated atherosclerosis with decreasing blood pressure and inhibited NF-kappaB and STAT3 activation, which was associated with suppression of inflammatory factor and atherogenic gene expression in the artery. In vitro studies demonstrated similar changes in AngII-treated VSMCs and macrophages: SIRT1 activation inhibited the expression levels of proinflammatory factor. These studies uncover crucial proinflammatory mechanisms of AngII and highlight actions of SIRT1 activation to inhibit AngII signaling, which is atheroprotective.

Go to